When randomized clinical trials are not available at the time a clinical decision needs to be made, clinicians often must choose between making decisions based on either observational data or no human data at all. A cautious use of observational data has been recently endorsed by the American Society of Clinical Oncology, which states that observational studies can “inform questions that either have not been or cannot be answered by randomized trials”
1(p1845) and “complement the evidence collected in randomized trials.”
1(p1845) Observational studies may be particularly important for patients who are underrepresented in trials, such as elderly patients.
2,3